SofWave Medical (SOFW) investor relations material

Operating performance and scale

• Q2 2026 revenue $29.96M, up 43% YoY; gross margin 76.5%; IFRS profit $2.5M.

• Usage fees reached $13.9M, up 52% YoY; 2021–2025 revenue CAGR was 42%, and recurring revenue was 43% of 2025 revenue.

• Cash was $38.8M at June 30, with no debt; $3.6M cash generated in Q2 2026; profitable since Q4 2024.

• 3,100 systems sold and over 1M treatments performed; sales reach expanded from 34 countries in 2025 to over 50.

Technology and business model

• Revenue combines console sales with recurring pulse utilization; providers use 150–200 pulses per face-and-neck treatment, with a stated U.S. procedure price of $2,500–$3,000.

• Provider economics include a 215% first-year device ROI in Q2 and a 4–6 month payback; practice gross margins cited at 70%–80%.

• Ultrasound targets the mid-dermal layer at 1.5–2.0 mm to stimulate collagen, hyaluronic acid and elastin while avoiding fat injury; over 10 patents issued and 50 office actions pending.

• Pure Impact VIP, introduced in 2026, targets functional strength; a blinded 38-patient study reported 65% average improvement after six treatments, sustained through week nine, with no adverse events.

Market and geographic expansion

• Management cited 9% global aesthetic-market CAGR through 2029 and sees GLP-1-related weight loss as a demand tailwind for skin lifting and tightening.

• China received NMPA clearance in September 2026; launch is planned for Q4 2026 with HEDK leading go-to-market, and management views the unit opportunity as potentially U.S.-scale.

• Japan clearance was achieved at the end of 2025; expansion is underway in Spain, Brazil and Germany, with a potential sales footprint of over 110 countries.

• 2026 growth reflected new markets, momentum in Japan and Korea, added U.S. sales and practice-development staff, and GLP-1 demand.